India Drug Industry Expects No Additional Budget Benefits
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical industry does not expect any particular benefit from the Union Budget 2008 being developed by a government facing upcoming national elections. The government has announced several populist health-care measures to benefit the public at large, including some favored by the Pharmaceutical and Biotechnology Industry. But the benefits are not expected to be as high as suggested. Benefits include weighted research-and-development deductions, reduced custom duty on certain drugs and reduction of excise duties on all drugs. (Click here for more